Results 151 to 160 of about 113,590,771 (217)

Prevalence, Disease Onset and Clinical Outcome in Arginase 1 Deficiency: Cross-Border Surveillance in Germany, Austria, and Switzerland. [PDF]

J Inherit Metab Dis
Scharre S, Hess AL, Gleich F, Garbade SF, Feyh P, Karall D, Baghdasaryan A, Huemer M, Hennermann JB, Hahn A, Lindner M, Gramer G, Luecke T, Kleinelanghorst N, Haeberle J, Lotz-Havla AS, Hoffmann GF, Okun JG, Muetze U, Kölker S.   +19 more
europepmc   +1 more source

Exosomes in Cancer: The Biology, Function, Diagnosis, and Therapy

MedComm, Volume 7, Issue 11, November 2026.
Tumor‐derived exosomes and nonmembranous extracellular nanoparticles (exomeres/supermeres) constitute a heterogeneous communication network that drives cancer progression. By shuttling functional biomolecules across tissue‐specific barriers, these nanoparticles orchestrate local microenvironmental remodeling, immune suppression, premetastatic niche ...
Jun Wu, Lei Wu, Kang Yang, Kang Xie, Tao Lu, Tiangxiang Huang, Dengfeng Wan, Tao Song, Longbo Zhang   +8 more
wiley   +1 more source

Adipose‐Derived Mesenchymal Stem Cells: Isolation, Origin, Phenotype Applications, and Challenges

MedComm, Volume 7, Issue 11, November 2026.
Bridging basic biology to clinical translation, this review systematically explores the in vivo origins and evolving isolation techniques of AD‐MSCs. We dissect their diverse phenotype applications orchestrated by immunometabolic reprogramming, mitochondrial transfer, and extracellular vesicles.
Ziyang Liu, Guangming Tu, Chao Wang, Hongyan Zhao, Ziyi Wu, Wei Li, Li Chen, Bailin Niu   +7 more
wiley   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang, Siwen Wu, Yusi Wang, Die Hu, Li Yang   +4 more
wiley   +1 more source

22. Myocyte-Mediated Arginase 1 Expression Controls Hyperargininemia But Not Hyperammonemia in the Arginase-Deficient Mouse [PDF]

Molecular Therapy, 2014
openaire   +1 more source

Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study. [PDF]

EClinicalMedicine
Ghosh A, Baghdasaryan A, Pinto PL, Rudebeck M.   +3 more
europepmc   +1 more source

Curcumin in the Treatment of Various Diseases: Mechanism of Action, Bioavailability, Therapeutic Effects, and Current Clinical Trials

MedComm, Volume 7, Issue 11, November 2026.
Curcumin, a naturally occurring polyphenol, exhibits significant anti‐inflammatory and antioxidant capabilities. This review elucidates the specific molecular mechanisms by which curcumin exerts therapeutic effects on various diseases, including neurological disorders, cardiovascular diseases, cancers, inflammatory disorders, and autoimmune diseases ...
Lin Wang, Qifei Pan, Wenjuan Long, Xinyao Li, Jianqin Mao, Sitong Zhou, Zihui Wang, Xuelian Zou, Yuqing She, Mingqin Shi, Yang Zhou, Jiarong Du, Zhongyang Hu, Xiaoman Lv, Yishu Chen, Dongdong Qin   +15 more
wiley   +1 more source

O08: Long-term efficacy and safety of pegzilarginase for arginase 1 deficiency: 2 years of experience in the phase 2 extension study*

Genetics in Medicine Open, 2023
Markey McNutt, George Diaz, Andreas Schulze, Gillian Bubb, Leslie Sloan, Elisa Leão-Teles, Spyros Batzios, Angela Sun, Allison Bannick, Roberto Zori, Gregory Enns   +10 more
doaj   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

Medicinal Research Reviews, Volume 46, Issue 6, Page 1477-1498, November 2026.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood, Jacinta R. Macdonald, Christian Anzenhofer, Tina S. Skinner‐Adams, Robert C. Reid, Thomas Kurz, David P. Fairlie, Katherine T. Andrews   +7 more
wiley   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source